Teclistamab in Relapsed or Refractory Multiple MyelomaPhilippe Moreau, Saad Z. Usmani, Laura Rosiñol et al.|New England Journal of Medicine|2022Cited by 1.2k
Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple MyelomaPhilippe Moreau, Amrita Krishnan, Saad Z. Usmani et al.|Blood|2021Cited by 40
P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMARakesh Popat, A Krishnan, Saad Z. Usmani et al.|HemaSphere|2022Cited by 3
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myelomaPhilippe Moreau, Saad Z. Usmani, Niels WCJ van de Donk et al.|Future Oncology|2023Cited by 2